MAOA and posterior cortical atrophy: Clorgyline, a selective MAO-A inhibitor for antidepression, was shown to suppress PCa progression in the mouse model25, and phenelzine, another MAO-A inhibitor, the FDA-approved drug for antidepression, is under phase II clinical trials for nonmetastatic recurrent PCa (ClinicalTrials.gov Identifier: NCT02217709).